ACRIVON THERAPEUTICS
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethal contexts. The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials.
ACRIVON THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Oncology Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.acrivon.com
Total Employee:
51+
Status:
Active
Total Funding:
245.5 M USD
Technology used in webpage:
CrUX Top 50m Bamboo HR
Similar Organizations
2seventy bio
2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment.
Biomea Fusion
Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.
Checkpoint Therapeutics
Checkpoint Therapeutics is a clinical-stage, immuno-oncology biopharmaceutical company.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Alumis
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Hummingbird Bioscience
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.
Leo Cancer Care
Leo Cancer Care constantly seeking to optimise and improve.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Acrivon Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Acrivon Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Acrivon Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Equity - Acrivon Therapeutics
Paradigm BioCapital Advisors
Paradigm BioCapital Advisors investment in Post-IPO Equity - Acrivon Therapeutics
Sands Capital Ventures
Sands Capital Ventures investment in Post-IPO Equity - Acrivon Therapeutics
Marshall Wace
Marshall Wace investment in Series B - Acrivon Therapeutics
HBM Healthcare Investments
HBM Healthcare Investments investment in Series B - Acrivon Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Series B - Acrivon Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Acrivon Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-03 | Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.acrivon.com Semrush global rank: 5.03 M Semrush visits lastest month: 1.62 K
Unable to get host informations!!!
More informations about "Acrivon Therapeutics"
About - Acrivon
The name Acrivon (derived from Greek for “accurate”) embodies how our OncoSignature tests link the patient’s active tumor-driving mechanisms with the drug’s mode-of-action to accurately match our therapies with patients who will …See details»
People - Acrivon
Acrivon’s team is a rare blend of leading scientific pioneers and highly accomplished executives. The team is located at two Centers of Excellence in Boston and Lund/Copenhagen in …See details»
Acrivon Therapeutics - Crunchbase Company Profile
Additionally, Acrivon Therapeutics announced a $130 million private placement financing, which provides substantial capital for the company's operations and growth initiatives. The appointment of a seasoned industry executive to the …See details»
Acrivon Therapeutics, Inc. | LinkedIn
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable …See details»
Acrivon Therapeutics, Inc. (ACRV) - Yahoo Finance
See the company profile for Acrivon Therapeutics, Inc. (ACRV) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Acrivon Company Profile - Office Locations, Competitors ... - Craft
Aug 27, 2024 Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision …See details»
Acrivon - Medicon Village
Acrivon is a clinical stage biotech company focused on developing and providing precision medicine solutions in oncology using our proprietary proteomics platform. The platform allows …See details»
Acrivon Therapeutics, Inc. (ACRV) - Yahoo Finance
Find the latest Acrivon Therapeutics, Inc. (ACRV) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Acrivon Therapeutics to Present Data Demonstrating Deployment …
Oct 17, 2024 Acrivon scientists to present data at two key scientific conferences demonstrating AP3’s proprietary and actionable machine learning-driven capabilities for drug discovery and …See details»
Acrivon Therapeutics, Inc. (ACRV) - Yahoo Finance Canada
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each …See details»
Acrivon Therapeutics Launches to Advance Clinical Oncology
Jun 29, 2021 Acrivon is a clinical stage oncology company leveraging its unique, proprietary phosphoproteomics technology called Acrivon Precision Predictive Proteomics, or AP3, in …See details»
Acrivon Therapeutics Closes Oversubscribed $100 Million
Nov 11, 2021 Acrivon is a clinical stage oncology company leveraging its unique, proprietary phosphoproteomics technology called Acrivon Precision Predictive Proteomics, or AP3, in …See details»
Acrivon Therapeutics Launches to Advance Clinical Oncology …
Jun 29, 2021 Acrivon is a clinical stage oncology company leveraging its unique, proprietary phosphoproteomics technology called Acrivon Precision Predictive Proteomics, or AP3, in …See details»
Acrivon Therapeutics Announces FDA has Granted Breakthrough …
Nov 28, 2023 Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to …See details»
Acrivon Therapeutics Announces Pricing of Initial Public Offering
WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical …See details»
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results …
WATERTOWN, Mass, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine …See details»
Clinical Trials - Acrivon
Clinical Trials. Clinical trials involve the administration of an investigational new drug to human subjects under the supervision of qualified investigators in accordance with good clinical …See details»
Acrivon Therapeutics (ACRV) Earnings Date and Reports 2025
1 day ago Get the Latest News and Ratings for ACRV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its …See details»
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR …
Acrivon Therapeutics, Inc • Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are …See details»
Science & Publications - Acrivon
Acrivon Predictive Precision Proteomics (AP3) Uncovers Mechanism of Resistance to ACR-368, a Clinical-Stage CHK1/2 Inhibitor, and Identifies Rational Combination Treatment (AACR, 2024) …See details»